--- title: "Why Is GH Research Stock Trading Higher on Thursday?" type: "News" locale: "en" url: "https://longbridge.com/en/news/292932378.md" description: "GH Research and Definium Therapeutics stocks rose following Eli Lilly's agreement to acquire AtaiBeckley for up to $3.8 billion. GH Research shares surged 11.40% as its lead drug GH001 draws comparisons to AtaiBeckley’s BPL-003, particularly regarding treatment-resistant depression applications and recent FDA clearance." datetime: "2026-07-16T16:36:18.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/292932378.md) - [en](https://longbridge.com/en/news/292932378.md) - [zh-HK](https://longbridge.com/zh-HK/news/292932378.md) --- # Why Is GH Research Stock Trading Higher on Thursday? **GH Research PLC** (NASDAQ:GHRS) and **Definium Therapeutics Inc.** (NASDAQ:DFTX) stocks are trading higher in response to **Eli Lilly and Co.** (NYSE:LLY) agreeing to acquire **AtaiBeckley Inc**. (NASDAQ:ATAI) in a deal valued at up to $3.80 billion. Bloomberg was the first to report the deal. AtaiBeckley is one of several companies poised to usher in this new era of psychedelics. **Read Also: Depression-Focused GH Research Shares Could See Significant Upside: Analyst** ## GH001 Draws Comparisons With AtaiBeckley’s Lead Drug Candidate GH Research’s lead drug, GH001, is formulated for mebufotenin administration via a proprietary inhalation approach, similar to AtaiBeckley’s lead asset, BPL-003 (mebufotenin benzoate), administered intranasally for treatment-resistant depression. ## Prior Data Supports Treatment-Resistant Depression Program In March 2026, the results of the Phase 2b trial in TRD (GH001-TRD-201) were published in JAMA Psychiatry. A post-hoc analysis reported alongside the publication demonstrated efficacy independent of the number of prior antidepressant treatment failures, with Day 8 remission rates of 53.9%-63.6% across subgroups. In May, GH Research said it completed enrolment in a Phase 1 pharmacology trial in the U.K., evaluating a proprietary aerosol delivery device for the administration of GH001 in healthy volunteers (GH001-HV-106). The company selected the doses for the global Phase 3 pivotal program based on the results from this trial for treatment-resistant depression. In January, the U.S. Food and Drug Administration (FDA) lifted the clinical hold on GH Research’s Investigational New Drug Application (IND) for GH001 after the FDA placed a clinical hold in September 2023 due to insufficient information to assess risks to human subjects. ## Shorter Treatment Duration For BPL-003 Bloomberg’s report on Thursday noted that BPL-003’s shorter treatment duration is a key advantage. Its psychedelic effects last about one to two hours, compared with some experimental therapies, including one from **Compass Pathways Plc** (NASDAQ:CMPS), that may require patient monitoring for up to eight hours. **Price Action:** GH Research shares were up 11.40% at $29.99, and Definium Therapeutics shares were down 1.31% at $45.06 at the time of publication on Thursday, according to Benzinga Pro data. **Read Also: Publix Closes More Stores in 2026 as Walmart Competition, Rising Costs and Online Grocery Shopping Bite: Here are the Locations Affected** _Photo: Shutterstock_ ### Related Stocks - [GHRS.US](https://longbridge.com/en/quote/GHRS.US.md) - [ATAI.US](https://longbridge.com/en/quote/ATAI.US.md) - [DFTX.US](https://longbridge.com/en/quote/DFTX.US.md) - [LLY.US](https://longbridge.com/en/quote/LLY.US.md) - [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md) - [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md) - [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md) - [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md) - [CMPS.US](https://longbridge.com/en/quote/CMPS.US.md) - [WMT.US](https://longbridge.com/en/quote/WMT.US.md) ## Related News & Research - [Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials](https://longbridge.com/en/news/293607076.md) - [First Trust Advisors LP Acquires 1,305 Shares of Eli Lilly and Company $LLY](https://longbridge.com/en/news/293719299.md) - [Lilly Targets Early 2027 Filing for Next Obesity Drug](https://longbridge.com/en/news/293649982.md) - [Eli Lilly's Retatrutide Meets Primary Endpoint In Phase 3 TRIUMPH-2 And TRIUMPH-3 Trials](https://longbridge.com/en/news/293605576.md) - [Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application](https://longbridge.com/en/news/293600518.md)